Abstract: Fullerene (C 60 ) is known to ef®ciently generate singlet oxygen when irradiated with light. In spite of such an unique photodynamic nature, little has been studied on biological functions of C 60 . This paper describes a tumor-therapeutic trial of C 60 based on the photoinduced generation of active oxygen. To achieve preferential accumulation of C 60 in the tumor tissue, this water-insoluble drug was chemically conjugated with poly(ethylene glycol) (PEG) not only to make it soluble in water but also to make the molecular size larger. When intravenously injected to tumor-bearing mice, the large-sized, as expected, water-soluble C 60 -PEG conjugate was accumulated to a greater extent and retained for a longer time period in the tumor tissue than in the normal issue. Following intravenous injection of the C 60 -PEG conjugate, local irradiation of visible light to the tumor site induced tumor necrosis, in contrast to the conjugate injection alone. When the C 60 dose was 8.48 mg/mouse, the tumor mass completely disappeared at an irradiation power of 107 J/cm 2 , indicating a high potentiality of the C 60 -PEG conjugate for photodynamic tumor therapy.
INTRODUCTION
While much attention has been paid to fullerenes on chemical and physical properties, few papers have been reported on their biological functions. One of the reasons may be the poor solubility of fullerene (C 60 ) in water. This water insolubility will prevent C 60 from directly interacting with biological substances and cells, resulting in no natural performance of biological functions. A mixed aqueous solution of C 60 and poly(vinyl pyrrolidone) is reported to induce differentiation of chondrocytes [1] . Moreover, it has been found that water-miscible C 60 derivatives inhibit HIV-1 protease activity [2] and proliferation of Hela S3 cells by visible-light irradiation [3] .
Photodynamic therapy on tumor is based on photo-induced generation of active oxygen. The conceptual illustration is shown in Fig. 1 . In advance, a photosensitizer with an af®nity for the tumor tissue is intravenously administered into the body. After tumor accumulation of the photosensitizer has become maximum, only the tumor site is selectively light-irradiated. At that time, the photo-chemical reaction shown in Fig. 1b occurs in the tumor tissue irradiated, resulting in destruction of the tumor tissue. The photosensitizer accumulated generates singlet oxygen from oxygen present in the tissue by light irradiation. The generated singlet oxygen is so reactive that acts as an effective cytotoxic agent [4] , destroying the surrounding tumor tissue.
C 60 is known to ef®ciently generate singlet oxygen when exposed to visible light [4] . We have demonstrated that light irradiation in the presence of C 60 gave cells a strong cytocidal effect in vitro [5] . Thus, if preferential accumulation of C 60 at a tumor tissue is achieved, it is possible that local irradiation of visible light to the tumor tissue results in selective tumor necrosis and C 60 functions as an effective photosensitizer for tumor photodynamic therapy. However, it is dif®cult to inject the water-insoluble C 60 into the body without solubilization in water, much less to expect its tumor targeting.
There are anatomical differences between the tumor and normal tissues (Fig. 2) . The substance permeability of blood vessels newly formed in the tumor tissue is generally higher than that of normal blood vessels. In addition to the hyperpermeable vasculature, it has been reported that immatured lymph systems in the tumor tissue makes it dif®cult to excrete large-sized substances from the tissue, enabling them to accumulate to a greater extent and retain for a longer time period at the tumor tissue than at the normal tissue [6±13]. An increase in accumulation and retention of antitumor drugs at the tumor tissue could be achieved by increasing their apparent molecular size through chemical conjugation with polymers [7, 8] . They are examples of passive drug targeting on the basis of the anatomical characteristics of tumor tissue.
The objective of this study is to passively target C 60 to the tumor tissue. When water-soluble polymers were intravenously injected to the tumor-bearing mice, their accumulation in the tumor tissue was higher than that in the normal tissue, irrespective of the polymer type [14±19]. The retained period of accumulated polymers was long compared with that in the normal tissue. If the apparent molecular size of water-insoluble C 60 is increased through conjugation with a water-soluble polymer, passive tumor targeting of C 60 will be realized in addition to its solubilization in water. Poly(ethylene glycol) (PEG) was selected as the water-soluble polymer for C 60 conjugation because it has been widely used for chemical modi®cation of drugs due to simple conjugation chemistry [20, 21] . It is likely that once accumulated in the tumor tissue, the C 60 -PEG conjugate remains for a long time period compared with that in the normal tissue. This pharmacodynamic difference, at a certain time period after injection, will enable C 60 to increase the ratio of tumor/normal tissue concentration, achieving so-called passive tumor targeting of C 60 . Then, only if the tumor site is light irradiated, it will be selectively destroyed (Fig. 3) . As expected, PEG conjugation results in enhanced accumulation of C 60 in the tumor tissue. In this paper, we describe feasibility of the C 60 -PEG conjugate as a photosensitizer for tumor photodynamic therapy showing its tumor therapeutic effect on mice carrying a tumor mass on the back subcutis. To our knowledge, no largesized, water-soluble C 60 has been applied for photodynamic therapy and this paper is the ®rst trial, although there have been reported some studies regarding polymerized C 60 and its modi®cation with polymers [22, 23] .
PREPARATION OF C 60 -PEG CONJUGATE
C 60 (99.9%, MW 720.66, Lot No. FHC03) was obtained from Tokyo Kasei Kogyo C. Ltd., Tokyo, Japan. Monomethoxy poly(ethylene glycol) with a primary amino group on the terminal was kindly supplied from Nippon Oil & Fats Company Ltd, Tokyo, Japan (PEG, MW 5460). Given amounts of PEG were mixed with C 60 in the benzene solution and coupling reaction was allowed to proceed under stirring at 25 8C for 24 h in the dark, followed by freeze-drying to obtain powdered C 60 -PEG conjugates. Gel ®ltration chromatographic studies revealed that the peak of PEG itself disappeared, a new peak being detected at a shorter retention time with C 60 conjugation. This clearly indicated that chemical coupling of PEG to C 60 actually took place. When estimated in terms of water/benzene partition, the solubility of C 60 -PEG conjugates in water increased with an increase in the PEG/C 60 molar ratio. When the PEG/C 60 ratio was 100, 100% of C 60 -PEG conjugates prepared was partitioned to the water phase. This completely water-soluble C 60 -PEG conjugate was used for the following in vivo experiments.
BODY DISTRIBUTION OF C 60 -PEG CONJUGATE FOLLOWING INTRAVENOUS INJECTION
Radioiodination of the C 60 -PEG conjugate was conducted according to a chloramine T method following their tyramine introduction [19] . Brie¯y, 2.7 mg of tyramine was added to a benzene solution containing 100 mg of C 60 -PEG conjugate at a tyramine/C 60 molar ratio of 100. After coupling reaction at 25 8C for 2 days, the resulting solution was dialyzed against water for 2 days to exclude non-coupled tyramine, followed by freeze-drying to obtain a tyramine-introduced C 60 -PEG conjugate. The tyramine-introduced C 60 -PEG conjugate was dissolved in 150 mL of 0.5 M potassium phosphate-buffered (KPB) solution (pH 7.5) to give a ®nal concentration of 50 mg/mL. Then, 2 mL of Na 125 I solution and 100 mL of 0.05 M KPB solution (pH 7.2) containing 0.02 mg of chloramine T were added to the C 60 -PEG conjugate solution. After agitation at 25 8C for 2 min, 100 mL of 0.01 M phosphate-buffered saline solution (PBS; pH 7.4) containing 0.4 mg of sodium pyrosul®te was added to stop the radioiodination. The resulting mixture was allowed to pass through a column of Dowex resin to remove uncoupled, free 125 I molecules from the 125 Ilabeled C 60 -PEG conjugate.
Meth A ®brosarcoma cells, which had been passaged in the peritoneal cavity of Balb/c female mice aged 6 weeks (Japan SLC Inc., Shizuoka, Japan), were inoculated at a volume of 50 mL into the back subcutis of female CDF 1 mice aged 6 weeks (Japan SLC Inc., Shizuoka, Japan) (3´10 6 cells/mouse). When the tumor mass grew at the inoculation site to 7 mm in the average diameter, tumor-bearing mice received intravenous injection of 100 mL of PBS solution containing 0.02 wt% of 125 I-labeled C 60 -PEG conjugates. At different time intervals, the radioactivity of blood samples, excised body tissues, and urine and faeces was measured with a gamma counter (Autowell gamma system Aloka ARC-301B, Aloka Company Ltd, Tokyo, Japan) for body distribution evaluation. Mouse skins (1.5´1.5 cm 2 ) with and without the tumor mass were taken out of tumor-bearing mice at their back subcutis and the radioactivity of both the skins was measured to calculate that of the tumor tissue itself from their difference. As normal controls, the skin and thigh muscle were taken to measure their radioactivity. Table 1 shows the body distribution of C 60 -PEG conjugates at different time intervals after intravenous injection. The C 60 -PEG conjugates disappeared with time from the blood circulation and approximately 78% of conjugates injected was excreted from the body 24 h after injection. Liver accumulation of the conjugates tended to increase up to 24 h after injection, but thereafter decreased to an undetectable level at 144 h after injection (data not shown). The conjugates accumulated in the gastrointestinal tract and carcass were eliminated with time to disappear from the sites, similarly to the liver. There was no speci®c af®nity of C 60 -PEG conjugates for organs. It is possible that intravenously injected conjugates are ®nally excreted from the kidney because their molecular size is small enough to undergo the glomerular ®ltration. Liver accumulation of C 60 -PEG conjugates during the initial 24 h after injection can be explained in terms of vascular permeability. Unlike other organs, liver vasculatures are composed of discontinuous vascular walls. The C 60 -PEG conjugate may be distributed in the extravascular tissue after intravenous injection, but return to the blood circulation by diffusion because the conjugate concentration in the blood is always low due to quick elimination by the blood stream [24] . If the conjugate has an af®nity for the liver, this phenomenon would not be observed. Table 2 shows the accumulation ratio of C 60 -PEG conjugates at the tumor tissue to those at the normal tissue. C 60 -PEG conjugates were accumulated in the tumor tissue to a signi®cantly higher extent than in the normal skin and muscle. It should be noted that the conjugates were retained in the tumor tissue at a signi®cantly higher amount and for a longer time period than in the normal tissue, although the accumulation amount at both the tissues tended to decrease with time. This is mainly ascribed to the anatomical feature of tumor tissues, e.g. the hyperpermeable vasculature and immatured lymph systems. Thus, it is likely that passive targeting of C 60 -PEG conjugates to the tumor tissue is achievable based on this difference. Indeed, when measured at 24 h after intravenous injection, the conjugate accumulation ratios of the tumor to the normal skin and muscle were 2.5 and 17, respectively, which clearly indicates the C 60 targeting to the tumor.
PHOTODYNAMIC THERAPY OF C 60 -PEG CONJUGATE ON TUMOR
For tumor therapeutic experiments, PBS solutions containing C 60 -PEG conjugates with given amounts of C 60 were intravenously injected to the tumor-bearing mice at an injection volume of 100 mL, and 24 h later, the tumor tissue was exposed to visible light (400±505 nm) from a light probe of 7 mm active diameter by Heliomat Multifunction Halogen-Light (Vivadent Co. Ltd, Liechtenstein). The light was delivered at a¯uence of 89.2 mW/cm 2 for 20 min (107 J/cm 2 ). For Photofrin, the dose was 4 mg/kg body and light irradiation (610±800 nm) was conducted at a¯uence of 72.5 mW/cm 2 (107 J/cm 2 ). The size of tumor grown was measured according to the method reported by Winn [25] and was expressed as the ratio of the tumor size to that before conjugate injection. As controls, the intravenous injection of C 60 -free PEG with or without the following light irradiation or light irradiation without any injection was performed to estimate the time pro®le of tumor growth.
Histological examination revealed that treatment with conjugate injection coupled with light irradiation, strongly induced tumor necrosis whereas the overlaying normal skin was not damaged. On the other hand, conjugate injection alone did not induce any tissue necrosis. This ®nding demonstrates that light irradiation is essential to induce destruction of the tumor tissue of mice receiving conjugate injection. When the back skin of the conjugate-injected normal mice was exposed to light at 89.2 mW/ cm 2 for 20 min, amounting to 107 J/cm 2 , after 24 h of injection, no histological damage of the skin was observed (data not shown). Figure 4 shows the photodynamic effect of C 60 -PEG conjugates and on the in vivo growth of tumor cells together with that of a clinically used photosensitizer, Photofrin. The photodynamic effect of C 60 -PEG conjugates on tumor greatly depended on the C 60 dose and the power of light irradiation. The in vivo suppression of growth by the conjugate increased with an increase in the irradiation power (Fig. 4A) . When the irradiation power was 107 J/cm 2 , the tumor size ratio became less than 1.0 after 4 days of injection and observation of all the mice for a longer time period revealed that the tumor mass disappeared. An increase in the C 60 dose of C 60 -PEG conjugate enhanced its photodynamic effect on tumor (Fig. 4B) . The size increase of the tumor mass was signi®cantly suppressed by conjugate injection followed by light irradiation at the C 60 dose more than 212 g/kg body. The treatment with the conjugate at the C 60 dose of 424 mg/kg body decreased the tumor size ratio to less than 1.0 and ®nally, all the tumorbearing mice were cured. The photodynamic effect of Photofrin on tumor was less ef®cient than that of the conjugate even at 10-times or more higher doses than the conjugate. Other studies demonstrated that the time pro®le of tumor growth of mice treated with C 60 -free PEG was similar to that of PBS-injected, control mice, irrespective of light irradiation. Light irradiation alone did not affect the tumor growth at all (data not shown). These ®ndings indicate that injection of C 60 itself is a key to achieve light-induced tumor suppression.
Since hematoporphyrin derivatives are complex mixtures of several compounds, the different components may have different pharmacokinetic and photodynamic properties. Moreover, these substances are retained in the skin for at least 4±6 weeks, thereby causing severe skin sensitization to sunlight [26] . Contrary to this, C 60 -PEG conjugates were excreted within 1 week by way of the kidney without such a long-term retention in normal tissues, implying their much less skin sensitization. This is because the conjugate, unlike hematoporphyrin derivatives, does not any speci®c af®nity for cell receptors. However, compared with Photofrin, the conjugate has a small optical extinction coef®cient in the wavelength region where light has its optimal penetration through tissue, i.e. in the 600±900 nm region [27] .
TOXICITY CONCERN
The in vivo toxicity of C 60 -PEG conjugates was evaluated in terms of the change of mouse body weight, histology, and blood examination of mice following their injection. When the time pro®le of body weight gain of normal mice intraperitoneally injected with C 60 -PEG conjugates with C 60 doses ranging from 3.6 mg/mouse to 36.0 mg/mouse was examined, no signi®cant difference was observed in the body weight change between all the groups (data not shown). The time pro®le was similar to that of PBS-injected, control mice. Moreover, intravenous injection of the conjugates did not affect the time pro®le of normal growth of mice. Blood examinations demonstrated that the plasma concentration of GOT, GPT, and BUN of tumor-bearing mice was not changed by the conjugate injection, irrespective of light irradiation, and was similar to that of PBS-injected, normal mice. Moreover, the histological appearance of liver tissue of mice receiving the conjugate injection was similar to that of the normal mice, irrespective of light irradiation. These ®ndings clearly indicate that conjugate injection followed by light irradiation neither exhibited systemic toxicity nor gave any damage to the liver and kidney.
CONCLUSION
Following intravenous injection of the PEG-C 60 conjugate, light irradiation to the tumor site strongly induced tumor necrosis without any damage to the overlaying normal skin. The conjugate was found to suppress the in vitro growth of normal cells when accompanied with light irradiation but did not exhibit any suppressive effect of cell growth without light irradiation [5] . It is very unlikely that the C 60 -PEG conjugate has cell selectivity for the cytotoxicity. Thus, this ®nding clearly indicates that the C 60 -PEG conjugate was present in the tumor tissue to a greater extent than in the normal tissue. As a result, the conjugates accumulated in the tumor tissue may be photodynamically activated by light irradiation to generate singlet oxygen, leading to the tumor necrosis without any damage to the normal tissue.
